NCT07616128PHASE2Recruiting
Study of EVO756 in Adults With Migraine
Evommune, Inc.
Start Date
6/1/2026
Completion Date
11/1/2027
Summary
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Eligibility Criteria
Age Range: 18 years to 64 years
Key Inclusion Criteria:
* Adults aged 18 to \<65 years
* Migraine with or without aura, per ICHD-3 criteria
* History of failure with prior preventive migraine treatments
* Not currently using migraine preventive therapy
Key Exclusion Criteria:
* Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders
* Use of certain medications
* Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities
Interventions
DRUG
EVO756, Dose 1
DRUG
EVO756, Dose 2
DRUG
Placebo
Conditions
Migraine
Locations
CA Medical Clinic for Headache
Los Angeles, California 90067
United States
New England Institute for Neurology and Headache
Stamford, Connecticut 06905
United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida 32256
United States
Apple Medical Research Group, Inc
Miami, Florida 331216
United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida 32819
United States
Vantage Clinical Trials
Tampa, Florida 33614
United States
Accel Research Site-Decatur-Alcanza
Decatur, Georgia 30030
United States
Michigan Headache and Neurological Institute
Ann Arbor, Michigan 48104
United States
Clinosis - Dent Neurologic Instite
Amherst, New York 14226
United States
Eximia Research NC
Raleigh, North Carolina 27607
United States
Clinical Trials of South Carolina
Charleston, South Carolina 29406
United States
FutureSearch Trials of Neurology
Austin, Texas 78731
United States
FutureSearch Trials of Dallas
Dallas, Texas 75251
United States
Vaught Neurological Services
Crab Orchard, West Virginia 25827
United States